Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

Repurposing drugs for treatment of Mycobacterium abscessus: a view to a kill.

Gumbo T, Cirrincione K, Srivastava S.

J Antimicrob Chemother. 2020 Feb 4. pii: dkz523. doi: 10.1093/jac/dkz523. [Epub ahead of print]

PMID:
32016429
2.

A Human Lung Challenge Model to Evaluate the Safety and Immunogenicity of PPD and Live BCG.

Davids M, Pooran A, Hermann C, Mottay L, Thompson F, Cardenas J, Gu J, Koeuth T, Meldau R, Limberis J, Gina P, Srivastava S, Calder B, Esmail A, Tomasicchio M, Blackburn J, Gumbo T, Dheda K.

Am J Respir Crit Care Med. 2019 Dec 20. doi: 10.1164/rccm.201908-1580OC. [Epub ahead of print]

PMID:
31860339
3.

Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis.

Ghafari N, Court R, Chirehwa MT, Wiesner L, Petersen L, Maartens G, Gumbo T, McIlleron H, Ramma L.

Int J Audiol. 2019 Nov 18:1-5. doi: 10.1080/14992027.2019.1690170. [Epub ahead of print]

PMID:
31739701
4.

Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics.

Srivastava S, Deshpande D, Magombedze G, van Zyl J, Cirrincione K, Martin K, Bendet P, Berg A, Hanna D, Romero K, Hermann D, Gumbo T.

J Antimicrob Chemother. 2020 Feb 1;75(2):392-399. doi: 10.1093/jac/dkz460.

5.

Effect of tablet crushing on drug exposure in the treatment of multidrug-resistant tuberculosis.

Court R, Chirehwa MT, Wiesner L, de Vries N, Harding J, Gumbo T, Maartens G, McIlleron H.

Int J Tuberc Lung Dis. 2019 Oct 1;23(10):1068-1074. doi: 10.5588/ijtld.18.0775.

PMID:
31627771
6.

Integrating pharmacokinetics and pharmacodynamics in operational research to End TB.

Alffenaar JC, Gumbo T, Dooley KE, Peloquin CA, McIlleron H, Zagorski A, Cirillo DM, Heysell SK, Silva DR, Migliori GB.

Clin Infect Dis. 2019 Sep 27. pii: ciz942. doi: 10.1093/cid/ciz942. [Epub ahead of print]

PMID:
31560376
7.

The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis.

Dheda K, Gumbo T, Maartens G, Dooley KE, Murray M, Furin J, Nardell EA, Warren RM; Lancet Respiratory Medicine drug-resistant tuberculosis Commission group.

Lancet Respir Med. 2019 Sep;7(9):820-826. doi: 10.1016/S2213-2600(19)30263-2. Review.

PMID:
31486393
8.

Dosing tuberculosis drugs in young children: the road ahead.

Pasipanodya JG, Gumbo T.

Lancet Child Adolesc Health. 2019 Sep;3(9):590-592. doi: 10.1016/S2352-4642(19)30180-4. Epub 2019 Jul 16. No abstract available.

PMID:
31324599
9.

Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation study.

Mehta K, Ravimohan S, Pasipanodya JG, Srivastava S, Modongo C, Zetola NM, Weissman D, Ivaturi V, Gumbo T, Bisson GP, Vinnard C.

J Antimicrob Chemother. 2019 Oct 1;74(10):2994-3002. doi: 10.1093/jac/dkz265.

PMID:
31273386
10.

Quantitative assessment of the activity of antituberculosis drugs and regimens.

Chirehwa MT, Velásquez GE, Gumbo T, McIlleron H.

Expert Rev Anti Infect Ther. 2019 Jun;17(6):449-457. doi: 10.1080/14787210.2019.1621747. Epub 2019 May 30.

PMID:
31144539
11.

Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models.

Ruth MM, Magombedze G, Gumbo T, Bendet P, Sangen JJN, Zweijpfenning S, Hoefsloot W, Pennings L, Koeken VACM, Wertheim HFL, Lee PS, van Ingen J, Deshpande D.

J Antimicrob Chemother. 2019 Jul 1;74(7):1952-1961. doi: 10.1093/jac/dkz143.

PMID:
31039251
12.

Detectable prednisolone is delayed in pericardial fluid, compared with plasma of patients with tuberculous pericarditis: A pilot study.

Shenje J, Gumbo T, Wiesner L, Ntsekhe M, Mayosi B, Ross I.

Int J Cardiol Heart Vasc. 2019 Jan 11;22:105-110. doi: 10.1016/j.ijcha.2018.12.008. eCollection 2019 Mar.

13.

Once-a-week tigecycline for the treatment of drug-resistant TB.

Deshpande D, Magombedze G, Srivastava S, Bendet P, Lee PS, Cirrincione KN, Martin KR, Dheda K, Gumbo T.

J Antimicrob Chemother. 2019 Jun 1;74(6):1607-1617. doi: 10.1093/jac/dkz061.

PMID:
30820554
14.

Spatial Network Mapping of Pulmonary Multidrug-Resistant Tuberculosis Cavities Using RNA Sequencing.

Dheda K, Lenders L, Srivastava S, Magombedze G, Wainwright H, Raj P, Bush SJ, Pollara G, Steyn R, Davids M, Pooran A, Pennel T, Linegar A, McNerney R, Moodley L, Pasipanodya JG, Turner CT, Noursadeghi M, Warren RM, Wakeland E, Gumbo T.

Am J Respir Crit Care Med. 2019 Aug 1;200(3):370-380. doi: 10.1164/rccm.201807-1361OC.

15.

Minocycline Immunomodulates via Sonic Hedgehog Signaling and Apoptosis and Has Direct Potency Against Drug-Resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Srivastava S, Martin KR, Athale S, van Zyl J, Antiabong J, Koeuth T, Lee PS, Dheda K, Gumbo T.

J Infect Dis. 2019 Feb 23;219(6):975-985. doi: 10.1093/infdis/jiy587.

PMID:
30597040
16.

Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment.

Bolhuis MS, Akkerman OW, Sturkenboom MGG, Ghimire S, Srivastava S, Gumbo T, Alffenaar JC.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S327-S335. doi: 10.1093/cid/ciy625.

PMID:
30496467
17.

Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!

Srivastava S, Deshpande D, Magombedze G, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S359-S364. doi: 10.1093/cid/ciy627.

18.

Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges.

Magombedze G, Pasipanodya JG, Srivastava S, Deshpande D, Visser ME, Chigutsa E, McIlleron H, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S349-S358. doi: 10.1093/cid/ciy623.

19.

The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis.

Srivastava S, Deshpande D, Nuermberger E, Lee PS, Cirrincione K, Dheda K, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S336-S341. doi: 10.1093/cid/ciy626.

20.

Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Mpagama SG, Bendet P, Srivastava S, Koeuth T, Lee PS, Bhavnani SM, Ambrose PG, Thwaites G, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S293-S302. doi: 10.1093/cid/ciy611.

21.

d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.

Deshpande D, Alffenaar JC, Köser CU, Dheda K, Chapagain ML, Simbar N, Schön T, Sturkenboom MGG, McIlleron H, Lee PS, Koeuth T, Mpagama SG, Banu S, Foongladda S, Ogarkov O, Pholwat S, Houpt ER, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S308-S316. doi: 10.1093/cid/ciy624.

22.

Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Srivastava S, Bendet P, Koeuth T, Bhavnani SM, Ambrose PG, Smythe W, McIlleron H, Thwaites G, Gumusboga M, Van Deun A, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S274-S283. doi: 10.1093/cid/ciy618.

23.

Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis.

Pasipanodya JG, Smythe W, Merle CS, Olliaro PL, Deshpande D, Magombedze G, McIlleron H, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S284-S292. doi: 10.1093/cid/ciy610.

24.

Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Mpagama SG, Srivastava S, Bendet P, Koeuth T, Lee PS, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S317-S326. doi: 10.1093/cid/ciy609.

25.

Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis.

Deshpande D, Srivastava S, Nuermberger E, Koeuth T, Martin KR, Cirrincione KN, Lee PS, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S342-S348. doi: 10.1093/cid/ciy612.

26.

Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs.

Gumbo T, Alffenaar JC.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S267-S273. doi: 10.1093/cid/ciy608.

27.

Mapping spatial locational trends of informal economic enterprises using mobile geographic information data in the city of in Harare, Zimbabwe.

Gumbo T, Geyer M, Moyo I, Moyo T.

Data Brief. 2018 Sep 18;20:1692-1699. doi: 10.1016/j.dib.2018.09.037. eCollection 2018 Oct.

28.

Effect of lidocaine on kanamycin injection-site pain in patients with multidrug-resistant tuberculosis.

Court RG, Wiesner L, Chirehwa MT, Stewart A, de Vries N, Harding J, Gumbo T, McIlleron H, Maartens G.

Int J Tuberc Lung Dis. 2018 Aug 1;22(8):926-930. doi: 10.5588/ijtld.18.0091.

29.

Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis.

Dheda K, Lenders L, Magombedze G, Srivastava S, Raj P, Arning E, Ashcraft P, Bottiglieri T, Wainwright H, Pennel T, Linegar A, Moodley L, Pooran A, Pasipanodya JG, Sirgel FA, van Helden PD, Wakeland E, Warren RM, Gumbo T.

Am J Respir Crit Care Med. 2018 Nov 1;198(9):1208-1219. doi: 10.1164/rccm.201711-2333OC.

30.

Clofazimine for the Treatment of Mycobacterium kansasii.

Srivastava S, Gumbo T.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00248-18. doi: 10.1128/AAC.00248-18. Print 2018 Aug.

31.

Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.

Zuur MA, Pasipanodya JG, van Soolingen D, van der Werf TS, Gumbo T, Alffenaar JC.

Clin Infect Dis. 2018 Nov 13;67(11):1743-1749. doi: 10.1093/cid/ciy346.

PMID:
29697766
32.

Pan-tuberculosis regimens: an argument against.

Dheda K, Gumbo T, Lange C, Horsburgh CR Jr, Furin J.

Lancet Respir Med. 2018 Apr;6(4):240-242. doi: 10.1016/S2213-2600(18)30097-3. No abstract available.

PMID:
29595502
33.

Individualizing Tuberculosis (TB) Treatment: Are TB Programs in High Burden Settings Ready for Prime Time Therapeutic Drug Monitoring?

Pasipanodya JG, Gumbo T.

Clin Infect Dis. 2018 Aug 16;67(5):717-718. doi: 10.1093/cid/ciy184. No abstract available.

PMID:
29514180
34.

Reply to Zimenkov, "Mutation in luxR Family Transcriptional Regulator Rv0890c Is Not a Marker of Linezolid Resistance".

Srivastava S, Gumbo T.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02296-17. doi: 10.1128/AAC.02296-17. Print 2018 Mar. No abstract available.

35.

Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis.

Court R, Wiesner L, Stewart A, de Vries N, Harding J, Maartens G, Gumbo T, McIlleron H.

Int J Tuberc Lung Dis. 2018 Jan 1;22(1):30-33. doi: 10.5588/ijtld.17.0475.

36.

Urine colorimetry for therapeutic drug monitoring of pyrazinamide during tuberculosis treatment.

Zentner I, Modongo C, Zetola NM, Pasipanodya JG, Srivastava S, Heysell SK, Mpagama S, Schlect HP, Gumbo T, Bisson GP, Vinnard C.

Int J Infect Dis. 2018 Mar;68:18-23. doi: 10.1016/j.ijid.2017.12.017. Epub 2017 Dec 15.

37.

Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis.

Deshpande D, Srivastava S, Bendet P, Martin KR, Cirrincione KN, Lee PS, Pasipanodya JG, Dheda K, Gumbo T.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02232-17. doi: 10.1128/AAC.02232-17. Print 2018 Feb.

38.

Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation.

Vinnard C, Ravimohan S, Tamuhla N, Pasipanodya J, Srivastava S, Modongo C, Zetola NM, Weissman D, Gumbo T, Bisson GP.

PLoS One. 2017 Nov 2;12(11):e0187624. doi: 10.1371/journal.pone.0187624. eCollection 2017.

39.

Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease.

Pasipanodya JG, Ogbonna D, Deshpande D, Srivastava S, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i3-i19. doi: 10.1093/jac/dkx311. Review.

PMID:
28922813
40.

A programme to create short-course chemotherapy for pulmonary Mycobacterium avium disease based on pharmacokinetics/pharmacodynamics and mathematical forecasting.

Deshpande D, Srivastava S, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i54-i60. doi: 10.1093/jac/dkx309.

PMID:
28922811
41.

A 'shock and awe' thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium-intracellulare complex disease.

Srivastava S, Deshpande D, Sherman CM, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i43-i47. doi: 10.1093/jac/dkx308.

PMID:
28922810
42.

A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease.

Deshpande D, Srivastava S, Pasipanodya JG, Lee PS, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i48-i53. doi: 10.1093/jac/dkx307.

PMID:
28922809
43.

The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent.

Deshpande D, Srivastava S, Chapagain ML, Lee PS, Cirrincione KN, Pasipanodya JG, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i36-i42. doi: 10.1093/jac/dkx306.

PMID:
28922808
44.

Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease.

Deshpande D, Srivastava S, Pasipanodya JG, Lee PS, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i30-i35. doi: 10.1093/jac/dkx305.

PMID:
28922807
45.

Linezolid as treatment for pulmonary Mycobacterium avium disease.

Deshpande D, Srivastava S, Pasipanodya JG, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i24-i29. doi: 10.1093/jac/dkx304.

PMID:
28922806
46.
47.

Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.

Deshpande D, Srivastava S, Chapagain M, Magombedze G, Martin KR, Cirrincione KN, Lee PS, Koeuth T, Dheda K, Gumbo T.

Sci Adv. 2017 Aug 30;3(8):e1701102. doi: 10.1126/sciadv.1701102. eCollection 2017 Aug.

48.

Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic science.

Alffenaar JC, Migliori GB, Gumbo T.

Lancet Infect Dis. 2017 Sep;17(9):898. doi: 10.1016/S1473-3099(17)30449-8. No abstract available.

PMID:
28845791
49.

pH Conditions under Which Pyrazinamide Works in Humans.

Srivastava S, Pasipanodya JG, Gumbo T.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00854-17. doi: 10.1128/AAC.00854-17. Print 2017 Sep. No abstract available.

50.

Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease Recurrence.

Pasipanodya JG, Ogbonna D, Ferro BE, Magombedze G, Srivastava S, Deshpande D, Gumbo T.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01206-17. doi: 10.1128/AAC.01206-17. Print 2017 Nov.

Supplemental Content

Support Center